Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: Experience from the FIN-RACo trial

Annals of the Rheumatic Diseases

Volumn 65, Issue 7, 2006, Pages 899-904

  Puolakka, K ^a   Kautiainen, H ^b   Pekurinen, M ^c   Mottonen T ^d   Hannonen, P ^e   Korpela, M ^f   Hakala, M ^b   Arkela Kautiainen, M ^b   Luukkainen, R ^g   Leirisalo Repo, M ^h  

^a Lappeenranta Central Hospital   (Finland)

^b RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

^g Rauma Hospital   (Finland)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; FOOT RADIOGRAPHY; HAND RADIOGRAPHY; HEALTH CARE COST; HUMAN; INCOME; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; INTERVENTION STUDY; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; PRIORITY JOURNAL; PRODUCTIVITY; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; WORK CAPACITY;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; FINLAND; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEX DISTRIBUTION; SICKNESS IMPACT PROFILE; WORK SCHEDULE TOLERANCE;

EID: 33745714550     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.045807     Document Type: Article

References (33)

1. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980;93:551-6.
2. Backman CL. Employment and work disability in rheumatoid arthritis. Curr Opin Rheumatol 2004;6:148-52.
3. Verstappen SM, Bijlsma JW, Verkleij H, Buskens E, Blaauw AA, ter Borg EJ, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004;51:488-97.
4. Hallert E, Husberg M, Jonsson D, Skogh T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology (Oxford) 2004;43:1374-82.
5. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29:305-20.
6. Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wang WK, Bulpitt KJ, et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western consortium of practicing rheumatologists. J Rheumatol 2000;27:1156-63.
7. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol 1996;23(suppl 44):47-51.
8. Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44:528-34.
9. Ruof J, Hulsemann JL, Mittendorf T, Handelmann S, von der Schulenburg JM, Zeidler H, et al. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on Healthcare payer's data sources. Ann Rheum Dis 2003;62:544-9.
10. World Health Organisation. International classification of functioning, disability and health. Geneva: WHO, 2001.
11. Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Julkunen H, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004;50:55-62.
12. Fries J, Spitz P, Kraines R, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
13. Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
14. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072-81.
15. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
16. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Phormacoeconomics 1996;10:400-6.
17. Cieza A, Brockow T, Ewert T, Amman E, Kollerits B, Chatterji S, et al. Linking health-status measurements to the international classification of functioning, disability and health. J Rehabil Med 2002;34:205-10.
18. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993.
19. Fienberg S. The analysis of cross-classified categorical data, 2nd edition. Cambridge, MA: MIT Press, 1980.
20. Merkesdal S, Ruof J, Huessemann JL, Mittendorf T, Handelmann S, Mau W, et al. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum 2005;53:234-40.
21. Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41.
22. Kavanaugh A, Han C, BaIa M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004;31:849-55.
23. van der Heijde D. Radiographic progression in rheumatoid arthritis: does it reflect outcome? Does it reflect treatment? Ann Rheum Dis 2001;60(suppl 3):47-50.
24. Scott D, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:122-32.
25. Sokka T, Kankainen A, Hannonen P. Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores. Arthritis Rheum 2000;43:386-9.
26. Sokka T, Pincus T. Markers for work disability in rheumatoid arthritis. J Rheumatol 2001;28:1718-22.
27. Lofland JH, Locklear JC, Frick KD. Different approaches to valuing the lost productivity of patients with migraine. Pharmacoeconomics 2001;19:917-25.
28. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13:563-9.
29. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54.
30. Wang PS, Beck A, Berglund P, Leutzinger JA, Pronk N, Richling D, et al. Chronic medical conditions and work performance in the health and work performance questionnaire calibration surveys. J Occup Environ Med 2003;45:1303-11.
31. Haque UJ, Bathon JM. The role of biologicals in early rheumatoid arthritis. Best Proof Res Clin Rheumatol 2005;19:179-89.
32. Stucki G, Ewert T, Cieza A. Value and application of the ICF in rehabilitation medicine. Disabil Rehabil 2002;24:932-8.
33. Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Hakala M, Korpela M, et al. Predictors of productivity loss and work disability in early rheumatoid arthritis: a 5-year followup study. Ann Rheum Dis 2005;64:130-3.